Difference between revisions of "Concizumab (Alhemo)"
Jump to navigation
Jump to search
(Created page with "Anti-TFPI antibody ==Supporting data== *'''explorer7:''' Matsushita T, Shapiro A, Abraham A, Angchaisuksiri P, Castaman G, Cepo K, d'Oiron R, Frei-Jones M, Goh AS, Haaning J,...") |
m |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
| + | ==Mechanism of action== | ||
Anti-TFPI antibody | Anti-TFPI antibody | ||
| Line 4: | Line 5: | ||
*'''explorer7:''' Matsushita T, Shapiro A, Abraham A, Angchaisuksiri P, Castaman G, Cepo K, d'Oiron R, Frei-Jones M, Goh AS, Haaning J, Hald Jacobsen S, Mahlangu J, Mathias M, Nogami K, Skovgaard Rasmussen J, Stasyshyn O, Tran H, Vilchevska K, Villarreal Martinez L, Windyga J, You CW, Zozulya N, Zulfikar B, Jiménez-Yuste V; explorer7 Investigators. Phase 3 Trial of Concizumab in Hemophilia with Inhibitors. N Engl J Med. 2023 Aug 31;389(9):783-794. [https://doi.org/10.1056/nejmoa2216455 link to original article] [https://pubmed.ncbi.nlm.nih.gov/37646676/ PubMed] [https://clinicaltrials.gov/study/NCT04083781 NCT04083781] | *'''explorer7:''' Matsushita T, Shapiro A, Abraham A, Angchaisuksiri P, Castaman G, Cepo K, d'Oiron R, Frei-Jones M, Goh AS, Haaning J, Hald Jacobsen S, Mahlangu J, Mathias M, Nogami K, Skovgaard Rasmussen J, Stasyshyn O, Tran H, Vilchevska K, Villarreal Martinez L, Windyga J, You CW, Zozulya N, Zulfikar B, Jiménez-Yuste V; explorer7 Investigators. Phase 3 Trial of Concizumab in Hemophilia with Inhibitors. N Engl J Med. 2023 Aug 31;389(9):783-794. [https://doi.org/10.1056/nejmoa2216455 link to original article] [https://pubmed.ncbi.nlm.nih.gov/37646676/ PubMed] [https://clinicaltrials.gov/study/NCT04083781 NCT04083781] | ||
| − | [[ | + | ==Also known as== |
| + | *'''Brand name:''' Alhemo | ||
| + | |||
| + | [[Category:Drugs]] | ||
[[Category:Anti-TFPI antibodies]] | [[Category:Anti-TFPI antibodies]] | ||
[[Category:Inherited coagulopathy medications]] | [[Category:Inherited coagulopathy medications]] | ||
Latest revision as of 13:12, 8 September 2023
Mechanism of action
Anti-TFPI antibody
Supporting data
- explorer7: Matsushita T, Shapiro A, Abraham A, Angchaisuksiri P, Castaman G, Cepo K, d'Oiron R, Frei-Jones M, Goh AS, Haaning J, Hald Jacobsen S, Mahlangu J, Mathias M, Nogami K, Skovgaard Rasmussen J, Stasyshyn O, Tran H, Vilchevska K, Villarreal Martinez L, Windyga J, You CW, Zozulya N, Zulfikar B, Jiménez-Yuste V; explorer7 Investigators. Phase 3 Trial of Concizumab in Hemophilia with Inhibitors. N Engl J Med. 2023 Aug 31;389(9):783-794. link to original article PubMed NCT04083781
Also known as
- Brand name: Alhemo